Combination therapy for the treatment of neuropathy

JP2024523413A5Active Publication Date: 2025-03-28TRANSFERT PLUS SEC
0 Cites 0 Cited by

Patent Information

Application Number
JP2023577985
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-16
Filing Date
2022-06-15
Publication Date
2025-03-28
Estimated Expiration
2042-06-15

AI Technical Summary

Technical Problem

Current treatments for intestinal neuropathies such as Hirschsprung's disease and enteric ganglion cell oligoplasia, including surgical removal of the aganglionic bowel, are associated with postoperative complications and do not fully address the need for regenerative medicine to restore distal colon motility and neurogenesis.

Method used

Administration of glial cell line-derived neurotrophic factor (GDNF) in combination with short-chain fatty acids (SCFAs) to induce neurogenesis and restore motility in the distal colon, potentially reducing the need for surgery.

Benefits of technology

The combination of GDNF and SCFAs enhances survival and improves distal colonic motility, epithelial barrier function, and neurogenesis in patients with intestinal neuropathies, offering a potential alternative to surgical intervention.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to a method for treating a human subject suffering from an enteric neuropathy or enteric hypoganglionosis, such as Hirschsprung's disease (HSCR), by administration of an effective dose of a combination comprising a glial cell line-derived neurotrophic factor (GDNF) polypeptide and a short chain fatty acid, such as butyrate.
Need to check novelty before this filing date? Find Prior Art